Abstract
AbstractIn the absence of sufficient (tax-based) healthcare financing in low-and middle-income countries, innovative financing models are needed. This study assessed quantitatively and qualitative the feasibility of a Development Impact Bond (DIB) for hepatitis C Virus (HCV) diagnosis and treatment in Cameroon. A revolving fund of up to €230,000 was made available by the investor. The outcome payor repaid the investor only in case of good performance, defined as cured patients (HCV-RNA negative). Identified HCV carriers were referred for treatment and tested for cure 12 weeks after completion of treatment, the outcome being validated by an independent party. The evaluation was guided by a recognized framework, involving interviews with relevant stakeholders (N= 22). In total, 253 (98%) patients completed treatment of which 244 (96%) are cured at week 24. We estimated that the average per patientoutcome paymentfor HCV diagnosis and treatment is €1,542 and theaverage costs per treated patientis €1,858. The investor was fully repaid including the agreed interest and bonus rate. The interviews confirmed the feasibility of the DIB in a low-resource setting. This study demonstrates that a DIB can be a suitable financing mechanism for HCV services, supporting the path towards elimination. When governments do not have sufficient resources to fund such elimination programs upfront, such public-private partnerships can offer a solution.HighlightsThe availability of a short-course highly effective hepatitis C treatment paves the way towards its elimination.We demonstrate feasibility of the first Development Impact Bond (DIB) as a financing mechanism for hepatitis C diagnosis and treatment.This study shows that with an average per patient outcome payment of €1,542, one HCV patient can be diagnosed and treated in a lower-middle income country.
Publisher
Cold Spring Harbor Laboratory
Reference19 articles.
1. Assessing hepatitis C spontaneous clearance and understanding associated factors—A systematic review and meta-analysis;Journal of Viral Hepatitis,2018
2. Development impact bonds: learning from the Asháninka cocoa and coffee case in Peru;Enterprise Development and Microfinance,2017
3. Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project;Tropical Medicine and International Health,2020
4. Drew, R. , & Clist, P. (2015). Evaluating Development Impact Bonds: A Study for DFID. https://www.gov.uk/dfid-research-outputs/evaluatingdevelopment-impact-bonds-a-study-for-dfid
5. Narratives of Promise, Narratives of Caution: A Review of the Literature on Social Impact Bonds;Social Policy & Administration,2018